X

Trial Profile

A Phase IIb Study Assessing Prophylactic Efficacy of Intranasal REVTx-99 in an H3N2 Influenza Challenge Model in Healthy Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyranosyl lipid adjuvant (Primary)
Indications Influenza virus infections
Focus Pharmacokinetics
Sponsors Revelation Biosciences

Most Recent Events

30 Mar 2022 Interim results presented in a Revelation Biosciences Media Release.
24 Mar 2022 According to a Revelation Biosciences Inc media release, the company has completed dosing for this study.
15 Mar 2022 According to a Revelation Biosciences Inc media release, company has completed enrollment and dosing in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com